Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NexImmune, Inc. (NEXI : OTC)

• Company Description    NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. NexImmune Inc. is based in GAITHERSBURG, Md. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $2.17 Daily Weekly Monthly 20 Day Moving Average: 2,474 shares Shares Outstanding: 1.39 (millions) Market Capitalization: $3.03 (millions) Beta: -2,282.12 52 Week High: $2.17 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2,169,900.25% 2,173,583.50% 12 Week 2,169,900.25% 2,134,906.75% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9119 GAITHER ROAD - GAITHERSBURG,MD 20877 USA ph: 301-825-9810 fax: - crubin@neximmune.com http://www.neximmune.com

• General Corporate Information    Officers Kristi Jones - President;ChiefExecutive Officer and Director Sol J. Barer - Chairperson of the Board of Directors Timothy Stover - Vice President; Corporate Controller Alan S. Roemer - Director Tim Bertram - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65344D208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 1.39 Most Recent Split Date: 10.00 (0.04:1) Beta: -2,282.12 Market Capitalization: $3.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - - Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - - Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - - Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©